FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	ourden								

0.5

hours per response:

	Check this box if no longer subject to
١	Section 16. Form 4 or Form 5
J	obligations may continue. See
	Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Shah Rajeev M.</u>						2. Issuer Name and Ticker or Trading Symbol KalVista Pharmaceuticals, Inc. [KALV]										all app Direc	licable) tor		erson(s) to I	
(Last) (First) (Middle) C/O RA CAPITAL MANAGEMENT, LLC						3. Date of Earliest Transaction (Month/Day/Year) 10/12/2017										Officer (give title below)			Other below	(specify
20 PARK PLAZA, SUITE 1200 (Street) BOSTON MA 02116 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)									Indivi	dividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transact Date (Month/Day							ion 2A. Deemed Execution Date,			quired, Disposed of, or Benefic 3. Transaction Code (Instr. 5) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 acquired)					or 5. Amount of Securities Beneficially			6. Ownership Form: Direct (D) or Indirect		7. Nature of Indirect Beneficial
										v	Amount		a) or	Price	Repor					Ownership (Instr. 4)
Common Stock 10/12/20						017			P		850,000	(1)	A	A \$8.5		5 1,441,070 ⁽²⁾			T I	See Footnote ⁽³⁾
		Та	ble II -								osed of, onvertib				/ Ow	ned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Da		Code (Ins				6. Date Exerci Expiration Dat (Month/Day/Ye		te	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)					9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)
				,	Code V		(A)	(D)	Date Exercisable		Expiration Date	Title		nber ires						

Explanation of Responses:

- 1. These securities include 684,902 shares held by RA Capital Healthcare Fund, L.P. (the "Fund") and 165,098 shares held in a separately managed account (the "Account").
- 2. Following the reported transactions, the Fund held 1,171,353 shares and the Account held 269,717 shares.
- 3. RA Capital Management, LLC (the "Adviser") is the general partner of the Fund and the investment adviser of the Account. Peter Kolchinsky is the sole manager of the Adviser, and Mr. Shah is a managing director of the Adviser. Mr. Shah has no pecuniary interest in the reported securities held in the Account and therefore disclaims beneficial ownership of those securities. Mr. Shah disclaims beneficial ownership of the reported securities held by the Fund except to the extent of his pecuniary interest therein.

/s/ Rajeev Shah

10/16/2017

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.